Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQH3906 in moderate to severe plaque psoriasis
NCT06542614Phase 2Completed
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Aug 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in plaque psoriasis comparing TQH3906 with Placebo (2 arms). Primary endpoint: Proportion of patients achieving Psoriasis Area and Severity Index 75% improvement at 12 weeks. Started Aug 2024; status: completed.
02
Drugs
TQH3906
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06542614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06542614.